FDA grants Orphan Drug Designation to ADoBind MC001 for the treatment of pancreatic cancer June 24, 2025
Positive Biomarker and Machine Learning Data from Ph 2 Elraglusib Trial in 1L Treatment of Metastatic Pancreatic Cancer Announced June 24, 2025
First Patient dosed in Ph 1 Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC) June 17, 2025
Nadunolimab awarded US FDA Fast Track Designation for the treatment of patients with metastatic PDAC with high IL1RAP expression levels June 17, 2025
FDA authorizes Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers June 17, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced May 13, 2025
Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer May 6, 2025
FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient March 26, 2025
Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer March 18, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
FDA RMAT Designation for CAR-NK in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer March 4, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
Positive Topline Results of Ph 3 COMPETE Trial with ITM-11 in Patients with Gr 1 or 2 GEP-NETs announced February 4, 2025
Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced February 4, 2025
ASCO GI 2025: Preliminary Cohort A Data from Ph 2 ASCEND Trial of Certepetide with SOC Chemo in Metastatic Pancreatic Ductal Adenocarcinoma reported January 28, 2025
Positive Update provided on Ph 2a Arm of IMM-1-104 in Combination with Modified FOLFIRINOX for 1L Pancreatic Cancer January 15, 2025
